<DOC>
	<DOCNO>NCT00708435</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety tolerance BERIPLEX® P/N ( Kcentra ) compare plasma regard rapid reversal coagulopathy induce coumarin derivative subject require immediate correction INR ( International Normalized Ratio ) stop acute major bleeding .</brief_summary>
	<brief_title>Efficacy Safety Study BERIPLEX® P/N ( Kcentra ) Compared With Plasma Patients With Acute Major Bleeding Caused Anticoagulant Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Protein C</mesh_term>
	<mesh_term>Protein S</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>Male female subject ≥ 18 year Subjects receive oral vitamin Kantagonist therapy Subjects acute major bleeding , define one following : lifethreatening potentially lifethreatening , acute bleeding associate fall hemoglobin ( Hb ) level ≥ 2g/dL , bleed require blood product transfusion INR ≥ 2 within 3 hour start study treatment Informed consent obtain Expected survival le 3 day , expect surgery le 1 day Acute trauma reversal vitamin K antagonists alone would expect control acute bleed event Use unfractionated low molecular weight heparin use 24 hour prior enrollment expect need within 24 hour start infusion For patient ICH : Glasgow coma score ( GCS ) &lt; 7 ; intracerebral hematoma volume &gt; 30cc assessed ABC/21 ; subdural hematoma : maximum thickness ≥ 10 mm , midline shift ≥ 5 mm ; subarachnoid hemorrhage : evidence hydrocephalus ; infratentorial ICH location ; epidural hematoma ; intraventricular extension hemorrhage ; modify Rankin score ( mRS ) &gt; 3 prior ICH History thrombotic event , myocardial infarction , disseminate intravascular coagulation , cerebral vascular accident , transient ischemic attack , unstable angina pectoris , severe peripheral vascular disease within 3 month enrollment Known history antiphospholipid antibody syndrome lupus anticoagulant antibody Suspected confirmed sepsis time enrollment Administration whole blood , plasma , plasma fraction platelet within 2 week prior inclusion study Large blood vessel rupture ( e.g . advanced cancer patient ) Preexisting progressive fatal disease life expectancy le 2 month Known inhibitor coagulation factor II , VII , IX , X ; hereditary protein C protein S deficiency ; heparininduced , type II thrombocytopenia Treatment investigational medicinal product within 30 day prior inclusion study Presence history hypersensitivity component study medication Pregnant breastfeeding woman Prior inclusion study CSL Behringsponsored Beriplex study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Anticoagulant reversal</keyword>
	<keyword>Prothrombin</keyword>
	<keyword>Complex</keyword>
	<keyword>Concentrate</keyword>
	<keyword>Coagulopathy</keyword>
	<keyword>induced</keyword>
	<keyword>coumarin</keyword>
	<keyword>derivative</keyword>
	<keyword>Kcentra</keyword>
</DOC>